Overcoming Ovarian Cancer Chemoresistance
- 1st Edition, Volume 11 - November 6, 2020
- Imprint: Academic Press
- Editors: Goli Samimi, Christina Annunziata
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 1 9 8 4 0 - 7
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 1 9 8 4 1 - 4
Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteOvercoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment.
The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future.
This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer.
- Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response
- Discusses genetic reversions as a unique alteration and a new field of study
- Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field
Cancer researchers, medical scientists, clinicians, graduate students
- Cover image
- Title page
- Table of Contents
- Copyright
- Cover Image Insert
- Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy”
- About the Series Editor
- Aims and Scope of Volume
- About the Volume Editors
- Preface
- Contributors
- Chapter 1: Epithelial ovarian cancer: Genomic landscape and evolving precision treatment
- Abstract
- Introduction
- Histological ovarian cancer subtypes
- Molecular alterations in ovarian cancer
- Primary treatment for ovarian carcinoma
- Systemic treatment of ovarian cancer recurrence
- Endocrine therapy in ovarian cancer
- Emerging therapies
- Conclusions
- Chapter 2: Overview of mechanisms of chemoresistance in ovarian cancer
- Abstract
- Introduction
- Cisplatin
- Taxanes
- PARP inhibitors
- Downstream survival mechanisms
- Conclusion
- Chapter 3: The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer
- Abstract
- Introduction
- Reversion mutations
- Detecting reversions
- Unresolved questions
- Conclusion
- Chapter 4: Ovarian cancer stem cell biology and chemoresistance
- Abstract
- Introduction
- Models of tumorigenesis
- Evidence for ovarian cancer stem cells
- Identifying ovarian cancer stem cells
- Properties of cancer stem cells
- Potential origins of ovarian cancer stem cells
- Methods to study ovarian cancer stem cells
- Targeting ovarian cancer stem cells
- Conclusion
- Chapter 5: The use of immunotherapy for treatment of chemoresistant ovarian cancer
- Abstract
- Introduction and significance
- Immune-based treatment of chemoresistant ovarian cancer
- Conclusions and future directions
- Chapter 6: Models of ovarian cancer to test new agents
- Abstract
- Introduction
- Human-derived models
- Animal models
- Extant challenge: Translation from cell and animal models to human treatments
- Chapter 7: Novel agents to target treatment resistance in ovarian cancer
- Abstract
- Introduction
- Chapter 8: Promising agents on the horizon
- Abstract
- Acknowledgment
- p53 reactivation: Chasing the “untargetable” to circumvent resistance
- Denosumab as a potential agent for ovarian cancer prevention
- Index
- Edition: 1
- Volume: 11
- Published: November 6, 2020
- No. of pages (Hardback): 188
- No. of pages (eBook): 188
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780128198407
- eBook ISBN: 9780128198414
GS
Goli Samimi
Dr Samimi currently serves as a Program Director in the Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, NCI. She manages the Ovarian Cancer Prevention portfolio and scientific monitoring of early phase ovarian cancer clinical trials within the NCI Division of Cancer Prevention Early Phase Prevention Consortia. Dr. Samimi’s research interests include molecular mechanisms of ovarian cancer etiology, circulating/shed DNA as a biomarker of ovarian cancer, and improving identification of high-risk individuals including BRCA1/2 mutation carriers. Dr. Samimi currently serves on the Trans-NCI Cancer and Bioethics Working Group, and the NCI Moonshot Generation of Human Tumor Atlases Implementation Team.
Affiliations and expertise
Program Director, The Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, NCICA
Christina Annunziata
Dr Annunziata is Principal Investigator and Clinical Director of the Women’s Malignancies Branch at the National Cancer Institute in Bethesda, Maryland. She received her MD and PhD from Georgetown University, and completed residency in Internal Medicine at that institution, followed by Medical Oncology Fellowship at the NCI. In the Intramural Program of the NCI, she runs a translational research laboratory and is involved with several clinical protocols. She has mentored both scientific and clinical fellows, who moved on to Assistant Professor positions, with independent grant funding. Outside the NIH, Dr. Annunziata has chaired grant review committees for ASCO and DOD.
Affiliations and expertise
Investigator, Women’s Malignancies Branch, Center for Cancer Research, NCI, USARead Overcoming Ovarian Cancer Chemoresistance on ScienceDirect